Original StudyResults of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
Introduction
Management of metastatic castration-resistant prostate cancer (mCRPC) has dramatically evolved within the past few years, with 6 agents having demonstrated an overall survival (OS) benefit: docetaxel (DOC), cabazitaxel (CABA), sipuleucel T (United States only), next-generation androgen receptor–targeted agents (ART) such as abiraterone acetate or enzalutamide, and radium-223.1 CABA has demonstrated an OS benefit similar to DOC in chemonaive mCRPC patients who did not receive an ART.2 Conversely, it prolongs OS in patients with progressive disease with or after DOC.3 It also retains activity in patients whose disease is progressing with receipt of ART.4
The challenge is to integrate this broad armamentarium rationally into daily practice and appropriately tailor therapies to optimize patient outcomes. However, the optimal sequencing of CABA with these other life-extending therapies is unknown because prospective randomized controlled trials are lacking.5, 6 Therefore, this noninterventional, observational study examined OS with various treatment sequences and sought to identify factors influencing OS in a real-life international cohort of mCRPC patients treated with CABA.
Section snippets
Patient Selection and Data Collection
Data were retrospectively collected (using an electronic case report form) from consecutive mCRPC patients (as per European Association of Urology definition1) treated between August 2012 and July 2016 at 44 centers in France, Spain, the United Kingdom, Greece, Poland, and Turkey. Patients were selected for inclusion in the study if they had received CABA for disease progression during or after DOC, with CABA administered as recommended—that is, at a dose of 25 mg/m2 (or exceptionally 20 mg/m2
Population Characteristics and Outcomes of Initiation of CABA
Overall, 574 mCRPC patients were treated with CABA in the participating centers according to 3 different sequences: group 1 (ADT → DOC → CABA), 267 patients; group 2 (ADT → DOC → ART → CABA), 183 patients; and group 3 (ADT → DOC → CABA → ART), 124 patients. Four patients received radium-223 as last therapy (1 patient in each of groups 1 and 2, and 2 patients in group 3); however, numbers were too small to perform any specific analysis.
Overall, 46.4% of patients had metastatic disease at
Discussion
To our knowledge, this is the largest cohort of mCRPC patients treated with CABA in real-life practice published to date. It documents outcomes of patients with mCRPC treated according to 3 different sequences of life-extending therapies: ADT → DOC → CABA only (historical arm because next-generation ART was not yet available at that time), ADT → DOC → CABA → ART, and ADT → DOC → ART → CABA. Results suggest that patients receiving 3 life-extending therapies (DOC, CABA, and ART, either
Conclusion
Our results suggest that OS of mCRPC patients increases with the number of life-extending therapies, with the greatest benefit being observed with a sequence including DOC, CABA, and ART. Limitations of a retrospective cohort apply. Randomized prospective trials are needed to confirm these data.
Disclosure
A.A. has received honoraria from Sanofi. S.O. has received consulting fees, travel support, and honoraria from Sanofi, Astellas, Bayer, and Janssen, and has served on advisory boards and lectured for Astellas, Sanofi, and Janssen. J.B. has received consulting fees, travel support, and honoraria from Sanofi, Astellas, and Janssen, and has served on advisory boards and lectured for Astellas, Sanofi, and Janssen. The other authors have stated that they have no conflict of interest.
Acknowledgments
English-language editing was provided by Andrea Bothwell. Supported in part by Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie (ARTIC) and by Sanofi and Janssen, France.
References (31)
- et al.
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
Eur Urol
(2017) - et al.
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Lancet
(2010) - et al.
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
Eur J Cancer
(2015) Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence
Eur Urol
(2014)- et al.
Charting recent progress and challenges in metastatic castration-resistant prostate cancer: is there an optimal treatment sequence?
Eur Urol Focus
(2016) - et al.
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
Eur J Cancer
(2014) - et al.
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer
Eur Urol
(2014) - et al.
Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices
Clin Genitourin Cancer
(2015) - et al.
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
Crit Rev Oncol Hematol
(2015) - et al.
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
Eur J Cancer
(2013)
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
Ann Oncol
Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer
Eur J Cancer
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Lancet Oncol
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Lancet
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study
Eur Urol
Cited by (19)
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands
2019, Clinical Genitourinary CancerCitation Excerpt :Median OS (mOS) in retrospective studies is shorter than in the interventional TROPIC, PROSELICA, and AFFINITY trials (real-world mOS of 7.0-12.7 months vs. trial mOS of 13.4-15.1 months, respectively).3,9-13 However, subgroups of patients treated with an extra life-prolonging drug (LPD) in third-line (postcabazitaxel) therapy do better with mOS, reaching 18.2 to 22.7 months.11,14-16 Patients in clinical trials are typically selected according to strict eligibility criteria, with the aim to include a homogeneous and fit population.17
Identification of the perturbed metabolic pathways associating with prostate cancer cells and anticancer affects of obacunone
2019, Journal of ProteomicsCitation Excerpt :Worse still, prostate cancer has no obvious symptoms until advanced phase. Various typical kinds of prostate cancer biomarkers in a combined way have been performed for early diagnosis, surgical therapy, radiation therapy, immunization therapy, androgen deprivation therapy and monitoring for devoting to increase the survival rate of illness [5–7]. At present, most of studies focused on seeking the specific signaling pathways, target regulatory elements of prostate cancer, but have been short of the pathophysiological mechanism exploration [8].
Targeted α-therapy using astatine (<sup>211</sup>At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
2023, European Journal of Nuclear Medicine and Molecular ImagingReal-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
2023, Expert Review of Pharmacoeconomics and Outcomes ResearchPrognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
2022, Translational Cancer Research